{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Altimmune, Inc."},"Symbol":{"label":"Symbol","value":"ALT"},"Address":{"label":"Address","value":"910 CLOPPER ROAD SUITE 201S, GAITHERSBURG, Maryland, 20878, United States"},"Phone":{"label":"Phone","value":"+1 240 654-1450"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV)."},"CompanyUrl":{"label":"Company Url","value":"https://www.altimmune.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bertrand Georges","title":"Chief Technology Officer"},{"name":"M. Scot Roberts","title":"Chief Scientific Officer"},{"name":"M. Scott Harris","title":"Chief Medical Officer"},{"name":"Vipin K. Garg","title":"President, Chief Executive Officer &amp; Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}